Eurobio Scientific Société anonyme (ALERS.PA)
- Previous Close
14.60 - Open
14.78 - Bid --
- Ask --
- Day's Range
14.46 - 14.78 - 52 Week Range
12.20 - 18.10 - Volume
3,782 - Avg. Volume
4,851 - Market Cap (intraday)
146.64M - Beta (5Y Monthly) -0.33
- PE Ratio (TTM)
33.72 - EPS (TTM)
0.43 - Earnings Date Apr 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients' immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.
www.eurobio-scientific.comRecent News: ALERS.PA
Performance Overview: ALERS.PA
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALERS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALERS.PA
Valuation Measures
Market Cap
146.64M
Enterprise Value
158.94M
Trailing P/E
33.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.25
Price/Book (mrq)
0.84
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
3.67%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
130.6M
Net Income Avi to Common (ttm)
4.8M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: ALERS.PA
Company Insights: ALERS.PA
ALERS.PA does not have Company Insights